Orchestra BioMed Holdings, Inc.
Orchestra BioMed, headquartered in New Hope, Pennsylvania, is a biomedical innovation company that develops therapeutic device candidates through strategic collaborations with medical device companies. Its pipeline includes bioelectronic therapies and interventional products, with AVIM Therapy and Virtue SAB as its flagship candidates. AVIM Therapy is a bioelectronic treatment candidate for uncontrolled hypertension designed to be integrated into cardiac pacemakers through firmware. Orchestra BioMed collaborates with Medtronic on its development; Medtronic has exclusive global commercialization rights for the pacemaker-indicated population following regulatory approval. Virtue SAB is a drug-device combination candidate designed to deliver sirolimus to artery walls during balloon angioplasty, without a coated balloon or permanent implant. Orchestra BioMed is conducting a U.S. pivotal study of Virtue SAB for coronary in-stent restenosis. The company’s partnership-enabled model shares development and commercialization responsibilities with established companies and is intended to generate revenue through product-related revenue shares and licensing arrangements.
RTW INVESTMENTS, LP purchased 1,200,000 indirectly-held shares of Orchestra BioMed Holdings, Inc. (OBIO) at $5.00 ($6.00M total) on 2026-11-09. Filed jointly with WONG RODERICK (10% owner).
Orchestra Biomed Holdings (OBIO) reported Q3 EPS of -$0.30, beating estimates by $0.10, but revenue of $91K missed expectations of $130.86K. The stock has risen 29.93% in the last 3 months and 29.64% in the last 12 months, closing at $5.73. InvestingPro rates its financial health as 'fair performance'.
Fain Eric S purchased 20,000 indirectly-held shares of Orchestra BioMed Holdings, Inc. (OBIO) at $5.00 ($0.10M total) on 2026-11-09.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning OBIO (Orchestra BioMed Holdings, Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 1 bearish.
Recent OBIO coverage spans insider activity, corporate actions and earnings.
In the last 30 days, OBIO insiders filed 6 SEC Form 4 transactions — 5 purchases ($6.2M) and 1 sale ($86K). The most active reporter was RTW INVESTMENTS, LP with 1 filing. 17% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider purchase suggests confidence and may lift the stock.
Mixed reaction expected as earnings beat offsets revenue shortfall.
The insider purchase may signal confidence from management, potentially supporting the stock price.
The insider purchase may create modest upward pressure on OBIO as it signals confidence from a director.
Small insider purchase may signal confidence but size is modest.
AlphAI scores every news story that mentions OBIO with an AI model for sentiment and relevance, and aggregates insider trades from Orchestra BioMed Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RTW INVESTMENTS, LP purchased 1,200,000 indirectly-held shares of Orchestra BioMed Holdings, Inc. (OBIO) at $5.00 ($6.00M total) on 2026-11-09. Filed jointly with WONG RODERICK (10% owner).
Orchestra Biomed Holdings (OBIO) reported Q3 EPS of -$0.30, beating estimates by $0.10, but revenue of $91K missed expectations of $130.86K. The stock has risen 29.93% in the last 3 months and 29.64% in the last 12 months, closing at $5.73. InvestingPro rates its financial health as 'fair performance'.
Fain Eric S purchased 20,000 indirectly-held shares of Orchestra BioMed Holdings, Inc. (OBIO) at $5.00 ($0.10M total) on 2026-11-09.
Pacitti David purchased 20,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $5.00 ($0.10M total) on 2026-11-09.
Hochman David P (See Remarks) purchased 5,000 indirectly-held shares of Orchestra BioMed Holdings, Inc. (OBIO) at $5.00 on 2026-11-09.
Taylor Andrew Lawrence (Chief Financial Officer) purchased 1,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $5.00 on 2026-11-09.
Orchestra BioMed Holdings, Inc. (OBIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Orchestra BioMed Announces Proposed Public Offering NEW HOPE, Pa., November 5, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patie
Orchestra BioMed (OBIO) priced a 15M share offering at $5 per share, raising $75M. Underwriters have a 30-day option for additional shares.
Orchestra BioMed (OBIO) priced a public offering of 15M shares at $X.XX/share, expecting $X.XXM gross proceeds to fund trials for hypertension and artery disease treatments. Piper Sandler and TD Cowen led the offering.
Orchestra BioMed (OBIO) will present its Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) at TCT 2026. The presentation will highlight the device's unique approach to delivering sirolimus for treating coronary in-stent restenosis. The Virtue Trial, comparing Virtue SAB to a commercially available drug-coated balloon, is currently enrolling. Preclinical and clinical evidence suggests Virtue SAB achieves higher sirolimus tissue concentrations and shows promising results in reducing restenosis.
